Probability of recurrence of thrombosis in patients with and without factor V Leiden

Thrombosis and Haemostasis

Volumn 75, Issue 2, 1996, Pages 229-232

  Rintelen, C ^a   Pabinger, I ^a   Knobl P ^a   Lechner, K ^a   Mannhalter, Ch ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0029930121     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650249     Document Type: Article

References (24)

1. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-90.
2. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Haematol 1991; 28: 10-8.
3. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: a study in three Dutch families. N Engl J Med 1983; 309: 340-4.
4. Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677-82.
5. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-45.
6. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Lechner K. The risk of thromboembolism in patients with protein S or protein C deficiency: prospective cohort study. Thromb Haemost 1994; 71 (4): 441-5.
7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
8. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
9. Griffin JH, Evatt B, Wideman C, Fernandez J. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
10. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
11. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-71.
12. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
13. Greengard JS, Sun X, Xu X, Fernandez JY. Griffin JH, Evatt B. Activated protein C resistance caused by Arg 506 Gln mutation in FVa. Lancet 1994; 343: 1361-2.
14. Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point mutation at Arg 506 of factor V. Lancet 1994; 343: 1535-6.
15. Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thromboembolism in apparently healthy men. N Engl J Med 1995; 332: 912-7.
17. Sarasiti F, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71 (3): 286-91.
18. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Clinical manifestations of inherited thrombophilia: a retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72 (3): 352-8.
19. Mannhalter C, Huber H, Löffler H, Faber V. Molekularbiologie in der medizinischen Diagnostik. In "Methoden der diagnostischen Hämatologie". Springer Verlag; Berlin, Heidelberg, New York 1994; 215-261.
20. Zöller B, Svensson P, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
21. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-7.
22. Khamashta MA, Cuadrano MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the anti-phospholipid-antibody syndrome. N Engl J Med 1995; 332 (15): 993-7.
23. Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52 (2): 127-30.
24. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Läfars G, Nicol P, Loogna E, Svensson E, Ljungeberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson KA, Hlorth M, Linder O, Borberg J and the duration of anticoagulant trial study group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.